Skip to Main Content

Chapter 96. Chronic Leukemias and Multiple Myeloma

First-line treatment options for newly diagnosed Ph positive chronic phase CML include:

A. Bosutinib, dasatinib, and imatinib

B. Bosutinib, imatinib, and ponatinib

C. Dasatinib, imatinib, and nilotinib

D. Imatinib, ponatinib, and omacetaxine

E. Imatinib, ibrutinib, and omacetaxine

Bosulif is in the class of drugs known as:

A. Antimetabolites

B. Immunomodulatory agents

C. Monoclonal antibodies

D. Proteasome inhibitors

E. Tyrosine kinase inhibitors

Patient counseling points for dasatinib include:

A. Avoiding iron preparations

B. Avoiding proton pump inhibitors

C. Discussing hand-foot syndrome

D. Discussing peripheral neuropathy

E. Taking with food

JH is a 42-year-old man with chronic phase CML who is being treated with imatinib. He fails to achieve a complete cytogenetic response by 12 months. Which is the most appropriate treatment option?

A. Continue imatinib

B. Switch to dasatinib

C. Switch to ponatinib

D. Switch to omacetaxine

E. Switch to ibrutinib

CP has chronic phase CML and has not achieved a complete hematologic and cytogenetic response on first-line therapy. Mutational analysis shows the T315I mutations. Which is the most appropriate treatment option?

A. Bosutinib

B. Dasatinib

C. Ibrutinib

D. Nilotinib

E. Ponatinib

The tyrosine kinase inhibitors used in CML inhibit:


B. Bruton pathway

C. Nuclear factor kappa B

D. Phosphatidylinositol-3

E. Vascular endothelial growth factor

Ponatinib has been associated with an increase in:

A. Arterial thrombotic events


Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.